See more : Niching Industrial Corporation (3444.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Avalon GloboCare Corp. (AVCO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avalon GloboCare Corp., a leading company in the Real Estate – Services industry within the Real Estate sector.
- Lennox International Inc. (LII) Income Statement Analysis – Financial Results
- China Dasheng Biotechnology Company (CDBT) Income Statement Analysis – Financial Results
- Jiangsu Hongdou Industrial Co., Ltd (600400.SS) Income Statement Analysis – Financial Results
- A.P. Møller – Mærsk A/S (AMKAF) Income Statement Analysis – Financial Results
- Mansi Finance (Chennai) Limited (MANSIFIN.BO) Income Statement Analysis – Financial Results
Avalon GloboCare Corp. (AVCO)
About Avalon GloboCare Corp.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 1.26M | 1.20M | 1.39M | 1.38M | 1.55M | 1.56M | 1.08M | 616.45K | 0.00 |
Cost of Revenue | 1.02M | 929.44K | 976.45K | 987.56K | 1.21M | 1.17M | 829.79K | 73.07K | 0.00 |
Gross Profit | 238.19K | 272.73K | 414.52K | 390.20K | 339.91K | 388.01K | 247.76K | 543.38K | 0.00 |
Gross Profit Ratio | 18.97% | 22.69% | 29.80% | 28.32% | 21.98% | 24.84% | 22.99% | 88.15% | 0.00% |
Research & Development | 109.62K | 731.33K | 1.03M | 883.86K | 1.78M | 39.06K | 0.00 | 0.00 | 0.00 |
General & Administrative | 5.64M | 5.66M | 8.22M | 11.96M | 16.93M | 7.68M | 2.79M | 459.55K | 31.01K |
Selling & Marketing | 1.67M | 1.33M | 328.57K | 294.35K | 685.06K | 335.90K | 15.25K | 6.89K | 0.00 |
SG&A | 7.31M | 6.98M | 8.22M | 11.96M | 16.93M | 8.02M | 2.80M | 466.45K | 31.01K |
Other Expenses | 8.57M | -120.51K | 4.27K | -4.98K | 3.26K | -11.35K | 0.00 | 0.00 | 0.00 |
Operating Expenses | 15.99M | 7.72M | 9.25M | 12.84M | 18.71M | 7.96M | 2.78M | 466.45K | 31.01K |
Cost & Expenses | 17.01M | 8.65M | 10.22M | 13.83M | 19.91M | 9.13M | 3.61M | 539.51K | 31.01K |
Interest Income | 0.00 | 3.58M | 200.48K | 168.76K | 82.91K | 4.31K | 1.37K | 575.00 | 0.00 |
Interest Expense | 1.35M | 3.58M | 200.48K | 168.76K | 82.91K | 314.65K | 138.11K | 0.00 | 0.00 |
Depreciation & Amortization | 329.95K | 466.28K | 438.78K | 378.48K | 506.74K | 522.84K | 181.64K | 26.00 | 175.51K |
EBITDA | -15.03M | -7.89M | -8.39M | -12.08M | -16.90M | -7.16M | -3.73M | 77.53K | -31.01K |
EBITDA Ratio | -1,196.61% | -593.84% | -607.58% | -880.57% | -1,192.42% | -454.97% | -218.21% | 12.48% | 0.00% |
Operating Income | -15.75M | -7.44M | -8.83M | -12.45M | -18.37M | -7.63M | -3.88M | 76.93K | -31.01K |
Operating Income Ratio | -1,254.59% | -619.12% | -635.08% | -903.93% | -1,187.81% | -488.46% | -359.88% | 12.48% | 0.00% |
Total Other Income/Expenses | -953.33K | -3.14M | -256.67K | -225.42K | 1.31M | -421.16K | -171.78K | 575.00 | 0.00 |
Income Before Tax | -16.71M | -11.93M | -9.09M | -12.68M | -18.07M | -8.05M | -4.05M | 77.51K | -31.01K |
Income Before Tax Ratio | -1,330.51% | -992.44% | -653.54% | -920.29% | -1,168.60% | -515.42% | -375.82% | 12.57% | 0.00% |
Income Tax Expense | 0.00 | 749.25K | 144.29K | 112.11K | 30.39K | -278.17K | -585.36K | 21.93K | -175.50K |
Net Income | -16.71M | -12.68M | -9.23M | -12.79M | -18.10M | -7.77M | -3.46M | 55.58K | -31.01K |
Net Income Ratio | -1,330.51% | -1,054.77% | -663.91% | -928.43% | -1,170.57% | -497.61% | -321.50% | 9.02% | 0.00% |
EPS | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
EPS Diluted | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
Weighted Avg Shares Out | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.20M | 6.50M | 5.11M | 175.00K |
Weighted Avg Shares Out (Dil) | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.20M | 6.50M | 5.11M | 175.00K |
Avalon GloboCare to continue US-centric strategy with new proposed board composition ahead of Laboratory Services MSO acquisition
Avalon GloboCare to acquire majority interest in Laboratory Services MSO in 'transformative' deal worth $31M
Stock Market Today: What Happened & 3 Penny Stocks To Watch Now
Avalon GloboCare gets notice of allowance from US patent office for QTY fusion platform
Avalon GloboCare says its co-developed QTY code protein code technology featured in Chemical Reviews
Avalon GloboCare reveals new study using AI-powered protein design technology targeting glucose transporter against cancer
Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference
Avalon GloboCare to team up with Lu Daopei Hematology Institute to develop companion diagnostics for CAR-T cancer treatments
Avalon GloboCare files 16 patent applications related to cellular therapies as company moves towards clinical trials
Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform
Source: https://incomestatements.info
Category: Stock Reports